Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus DYAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus DYAZIDE.
ATACAND HCT vs DYAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
None Documented
None Documented
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Triamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Category C
Category C
Angiotensin II Receptor Blocker / Thiazide Diuretic
Thiazide Diuretic